First-Ever Bespoke Base-Editing Therapy Developed in Months Saves Infant with Rare Genetic Disease

In a watershed moment for precision medicine, an infant born with a fatal genetic disorder has been successfully treated with a bespoke CRISPR base-editing therapy designed, manufactured, and administered in just six months. The landmark intervention represents the first time a personalized, in vivo gene-editing treatment has been rapidly developed for a single human patient, offering a tangible template for addressing ultra-rare diseases that traditional pharmaceutical models leave behind.[1][2][3]

The patient, KJ Muldoon, was diagnosed shortly after his birth in August 2024 with severe carbamoyl phosphate synthetase 1 (CPS1) deficiency. The condition is an ultra-rare metabolic disorder that affects approximately one in 1.3 million newborns.[1][3][6]

The disease mechanism is catastrophic: CPS1 deficiency disables the liver's ability to process nitrogen waste generated from the breakdown of dietary protein. Without a functional CPS1 enzyme, ammonia rapidly accumulates in the bloodstream to toxic levels, leading to irreversible neurological damage, coma, and an estimated 50 percent mortality rate during early infancy.[1][2][4]

Standard care for the condition relies on severely restricted protein diets and heavy doses of nitrogen-scavenging medications. While a liver transplant can provide a functional urea cycle and long-term survival, infants with severe presentations are often too small to safely undergo the surgery before suffering permanent brain damage.[2][3]

Facing a grim prognosis and a rapidly closing window for intervention, a multidisciplinary team from the Children's Hospital of Philadelphia (CHOP), Penn Medicine, and the University of California, Berkeley's Innovative Genomics Institute initiated an unprecedented "N-of-1" medical rescue.[2][5]

Genomic sequencing revealed that the infant carried a specific single-nucleotide mutation in both copies of his CPS1 gene. Because the defect was a single-letter error in the genetic code, the research team opted for base editing—a next-generation CRISPR technique that chemically flips a mutated DNA base to the correct letter without severing the DNA double helix, thereby reducing the risk of unintended large-scale genetic deletions.[1][4][5]

Operating under emergency conditions, the researchers designed a customized base editor, dubbed "k-abe," tailored exclusively to the infant's unique mutation. They validated the construct's efficacy in cell models and mice, compressing a preclinical development process that typically spans several years into a matter of weeks.[2][5]

To deliver the therapy directly to the liver, the genetic instructions were packaged inside lipid nanoparticles—microscopic fat bubbles similar to the delivery vehicles used in mRNA COVID-19 vaccines. These nanoparticles were engineered to be taken up specifically by hepatocytes, the liver cells where the CPS1 enzyme is naturally produced.[1][4]

In February 2025, at roughly six months of age, the infant received his first intravenous infusion of the bespoke therapy. The procedure marked a historic milestone: the first time a customized base-editing medicine had ever been administered directly into a living human body.[1][3][6]

The clinical evidence of efficacy emerged rapidly. According to the landmark study detailing the case in the New England Journal of Medicine, the infant's blood ammonia levels stabilized following the initial low-dose infusion and a subsequent higher dose administered weeks later.[1][2]

Within seven weeks of the first treatment, the infant was able to tolerate a significantly increased amount of dietary protein. Concurrently, his reliance on nitrogen-scavenging medications was reduced to half of the starting dose. Crucially, he avoided dangerous ammonia spikes even while fighting off common viral infections, which are notorious triggers for severe metabolic crises in patients with CPS1 deficiency.[1][2][4]

The NEJM data indicates that the treatment was well-tolerated, with no severe adverse events reported during the initial follow-up period. To mitigate the risk of off-target edits—unintended changes elsewhere in the genome—the team employed extensive preclinical computational screening and specialized assays, though researchers acknowledge that any permanent genomic alteration carries inherent long-term risks.[1][5]

Despite the profound short-term success, transparent uncertainty remains regarding the therapy's ultimate durability. Because a child's liver grows rapidly during early development, it is currently unknown whether the edited hepatocytes will proliferate sufficiently to maintain the therapeutic effect, or if unedited cells will eventually outcompete them and necessitate a future liver transplant.[1][3]

Furthermore, the long-term safety profile of in vivo base editing requires lifelong monitoring. While the infant is currently thriving and meeting developmental milestones, the medical community cautions that the success of a single N-of-1 trial does not guarantee identical safety or efficacy outcomes for other bespoke genetic interventions.[1][4]

The rapid deployment of this therapy has already catalyzed a paradigm shift in regulatory frameworks for ultra-rare diseases. In early 2026, the U.S. Food and Drug Administration introduced draft guidance for a "plausible mechanism framework," a pathway designed to allow platform technologies like CRISPR to be customized for individual patients without requiring a ground-up regulatory application for every unique genetic variant.

Under this new framework, the Cas9 protein and the lipid nanoparticle delivery system remain constant, while only the guide RNA sequence changes between patients. This regulatory flexibility is viewed as a transformative step toward making personalized genomic medicine scalable and accessible.

The successful rescue of Baby KJ represents a definitive transition for CRISPR technology from a broad therapeutic concept to a highly personalized, rapid-response clinical reality. By establishing a reproducible template for bespoke intervention, the case offers a tangible lifeline to millions of patients worldwide whose genetic mutations were previously considered too rare to treat.[2][3]